Home › Cancro del polmone non a piccole cellule › Illinois › Bloomington
Studi clinici su Cancro del polmone non a piccole cellule a Bloomington, IL
11 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Bloomington e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
In reclutamentoFase 3
- Illinois CancerCare-Bloomington, Bloomington
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
In reclutamentoFase 2
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
In reclutamentoFase 3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · a 2 mi di distanza
- Carle Cancer Institute Normal, Normal · a 2 mi di distanza
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
In reclutamentoFase 3
- Illinois CancerCare- Bloomington, Bloomington
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Illinois CancerCare - Bloomington, Bloomington
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
In reclutamentoFase 2
- Illinois CancerCare-Bloomington, Bloomington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Illinois CancerCare-Bloomington, Bloomington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2/3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · a 2 mi di distanza
- Carle Cancer Institute Normal, Normal · a 2 mi di distanza
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
In reclutamentoStudio osservazionale
- Illinois CancerCare-Bloomington, Bloomington
- Carle Cancer Institute Normal, Normal · a 2 mi di distanza
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Altri studi a Bloomington
- Cancro ai polmoni9 studi
- Cancro alla prostata7 studi
- Cancro colorettale7 studi
- Carcinoma a cellule squamose della testa e del collo6 studi
- Cancro pancreatico5 studi
- Melanoma5 studi
- Cancro dell'ipofaringe5 studi
- Cancro della laringe5 studi
- Cancro orale5 studi
- Cancro al seno5 studi
- Cancro al rene (carcinoma a cellule renali)4 studi
- Leucemia mieloide acuta4 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.